Therefore, HO‐1 inducer‐loaded PBP‐NPs were considered to be novel therapeutics for obesity‐induced metabolic syndromes such as T2DM and NASH occurred by adipose tissue dysfunction with excessive NEFA, inflammation, and oxidative stress. Here, HMOX1 is linked to type 2 diabetes mellitus.